Gynecologic Cancer InterGroup (GCIG) Consensus Review: Uterine and Ovarian Leiomyosarcomas

Overview

Journal Int J Gynecol Cancer

Specialties Gynecology & Obstetrics
Oncology

Date 2014 Oct 25

PMID 25341583

Citations 19

Authors

Martee L Hensley

Brigitte A Barrette

Klaus Baumann

David Gaffney

Anne L Hamilton

Jae-Weon Kim

Johanna U Maenpaa

Patricia Pautier

Nadeem Ahmad Siddiqui

Anneke M Westermann

Isabelle Ray-Coquard

Affiliations

Soon will be listed here.

Abstract

Objectives: The Gynecologic Cancer InterGroup aimed to provide an overview of uterine and ovarian leiomyosarcoma management.

Methods: Published articles and author experience were used to draft management overview. The draft manuscript was circulated to international members of the Gynecologic Cancer InterGroup for review and comment, and appropriate revisions were made.

Results: The approach to management of uterine and ovarian leiomyosarcoma management is reviewed.

Conclusions: Uterine and ovarian leiomyosarcomas are rare and aggressive cancers that require specialized expertise for optimal management.

Citing Articles

Primary Ovarian Leiomyosarcoma: A Case Report and Review of the Literature.

Elghanmi A, Kouhen F, Abdallaoui Maane L, Fichtali K, Ghazi B Cureus. 2025; 17(1):e78005.

PMID: 40007914 PMC: 11855805. DOI: 10.7759/cureus.78005.

Primary Ovarian Leiomyosarcoma Is a Very Rare Entity: A Narrative Review of the Literature.

Mandato V, Torricelli F, Mastrofilippo V, Palicelli A, Costagliola L, Aguzzoli L Cancers (Basel). 2023; 15(11).

PMID: 37296915 PMC: 10252074. DOI: 10.3390/cancers15112953.

Primary ovarian leiomyosarcoma in a woman with uterovaginal prolapse.

Bahadur A, Mundhra R, Verma P, Phulware R BMJ Case Rep. 2022; 15(9).

PMID: 36162964 PMC: 9516082. DOI: 10.1136/bcr-2022-251733.

Metastatic Pattern of Truncal and Extremity Leiomyosarcoma: Retrospective Analysis of Predictors, Outcomes, and Detection.

Tigchelaar S, Frey C, Sivaraj D, Segovia N, Mohler D, Steffner R J Pers Med. 2022; 12(3).

PMID: 35330345 PMC: 8949223. DOI: 10.3390/jpm12030345.

Identification of Somatic Genetic Alterations Using Whole-Exome Sequencing of Uterine Leiomyosarcoma Tumors.

Chen L, Li J, Wu X, Zheng Z Front Oncol. 2021; 11:687899.

PMID: 34178683 PMC: 8226214. DOI: 10.3389/fonc.2021.687899.

References

Muss H, Bundy B, Disaia P, Homesley H, Fowler Jr W, Creasman W . Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer. 1985; 55(8):1648-53. DOI: 10.1002/1097-0142(19850415)55:8<1648::aid-cncr2820550806>3.0.co;2-7. View

Hensley M, Blessing J, DeGeest K, Abulafia O, Rose P, Homesley H . Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008; 109(3):323-8. PMC: 2692926. DOI: 10.1016/j.ygyno.2008.02.024. View

Goff B, Rice L, Fleischhacker D, Muntz H, Falkenberry S, Nikrui N . Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol. 1993; 50(1):105-9. DOI: 10.1006/gyno.1993.1172. View

Bell S, Kempson R, Hendrickson M . Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994; 18(6):535-58. View

Reed N, Mangioni C, Malmstrom H, Scarfone G, Poveda A, Pecorelli S . Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008; 44(6):808-18. DOI: 10.1016/j.ejca.2008.01.019. View

Lavie O, Barnett-Griness O, Narod S, Rennert G . The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer. 2008; 18(2):352-6. DOI: 10.1111/j.1525-1438.2007.01025.x. View

Hensley M, Blessing J, Mannel R, Rose P . Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008; 109(3):329-34. PMC: 2504727. DOI: 10.1016/j.ygyno.2008.03.010. View

Einstein M, Barakat R, Chi D, Sonoda Y, Alektiar K, Hensley M . Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. Int J Gynecol Cancer. 2007; 18(5):1065-70. DOI: 10.1111/j.1525-1438.2007.01126.x. View

Gonzalez K, Noltner K, Buzin C, Gu D, Wen-Fong C, Nguyen V . Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009; 27(8):1250-6. DOI: 10.1200/JCO.2008.16.6959. View

10.

Zivanovic O, Leitao M, Iasonos A, Jacks L, Zhou Q, Abu-Rustum N . Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol. 2009; 27(12):2066-72. PMC: 3646302. DOI: 10.1200/JCO.2008.19.8366. View

11.

Pelmus M, Penault-Llorca F, Guillou L, Collin F, Bertrand G, Trassard M . Prognostic factors in early-stage leiomyosarcoma of the uterus. Int J Gynecol Cancer. 2009; 19(3):385-90. DOI: 10.1111/IGC.0b013e3181a1bfbc. View

12.

DAngelo E, Prat J . Uterine sarcomas: a review. Gynecol Oncol. 2009; 116(1):131-9. DOI: 10.1016/j.ygyno.2009.09.023. View

13.

OCearbhaill R, Zhou Q, Iasonos A, Soslow R, Leitao M, Aghajanian C . Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol. 2009; 116(3):424-9. PMC: 4852374. DOI: 10.1016/j.ygyno.2009.10.064. View

14.

Cornfeld D, Israel G, Martel M, Weinreb J, Schwartz P, McCarthy S . MRI appearance of mesenchymal tumors of the uterus. Eur J Radiol. 2009; 74(1):241-9. DOI: 10.1016/j.ejrad.2009.03.005. View

15.

Wang W, Soslow R, Hensley M, Asad H, Zannoni G, De Nictolis M . Histopathologic prognostic factors in stage I leiomyosarcoma of the uterus: a detailed analysis of 27 cases. Am J Surg Pathol. 2011; 35(4):522-9. DOI: 10.1097/PAS.0b013e31820ca624. View

16.

Kao Y, Saad U, Tan A, Magsombol B, Padhy A . Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas. Acta Radiol. 2011; 52(4):463-6. DOI: 10.1258/ar.2011.100509. View

17.

Arslan O, Sumer C, Cihangiroglu G, Kanat-Pektas M, Gungor T . A rare tumor of the female genital tract: primary ovarian leiomyosarcoma. Arch Gynecol Obstet. 2010; 283 Suppl 1:83-5. DOI: 10.1007/s00404-010-1735-3. View

18.

Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, Martin J, Martinez-Trufero J, Casado A . Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011; 29(18):2528-33. DOI: 10.1200/JCO.2010.33.6107. View

19.

Park J, Park S, Kim D, Kim J, Kim Y, Kim Y . The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol. 2011; 122(2):255-9. DOI: 10.1016/j.ygyno.2011.04.021. View

20.

Burt B, Ocejo S, Mery C, Dasilva M, Bueno R, Sugarbaker D . Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival. Ann Thorac Surg. 2011; 92(4):1202-7. DOI: 10.1016/j.athoracsur.2011.05.052. View